FLUDEOXYGLUCOSE (F-18) SOLUTION
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
09-03-2017
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
FLUDEOXYGLUCOSE 18F
Dostupné z:
LAWSON HEALTH RESEARCH INSTITUTE
ATC kód:
V09IX04
INN (Medzinárodný Name):
FLUDEOXYGLUCOSE (18F)
Dávkovanie:
232GBQ
Forma lieku:
SOLUTION
Zloženie:
FLUDEOXYGLUCOSE 18F 232GBQ
Spôsob podávania:
INTRAVENOUS
Počet v balení:
20ML
Typ predpisu:
Schedule C
Terapeutické oblasti:
ROENTGENOGRAPHY
Prehľad produktov:
Active ingredient group (AIG) number: 0152591014; AHFS:
Stav Autorizácia:
APPROVED
Dátum Autorizácia:
2018-10-02
Súhrn charakteristických
Fludeoxyglucose (
18
F)
1
PRODUCT MONOGRAPH
TRADE NAME
Fludeoxyglucose (
18
F) Injection
0.5 to 232 GBq/vial
Diagnostic Radiopharmaceutical
Lawson Health Research Institute
268 Grosvenor Street
London ON N6A 4V2
Date of Approval:
March 9, 2017
Control #:
197018
Fludeoxyglucose (
18
F)
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
DESCRIPTION
...............................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
4
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
6
DOSAGE AND ADMINISTRATION
...........................................................................................
7
RADIATION DOSIMETRY
..........................................................................................................
9
OVERDOSAGE............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
12
DOSAGE FORM
Prečítajte si celý dokument
